It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
The International Consensus on Antinuclear Antibody (ANA) Patterns (ICAP) has recently proposed nomenclature in order to harmonize ANA indirect immunofluorescence (IIF) pattern reporting. ICAP distinguishes competent-level from expert-level patterns. A survey was organized to evaluate reporting, familiarity, and considered clinical value of ANA IIF patterns.
Methods
Two surveys were distributed by European Autoimmunity Standardization Initiative (EASI) working groups, the International Consensus on ANA Patterns (ICAP) and UK NEQAS to laboratory professionals and clinicians.
Results
438 laboratory professionals and 248 clinicians from 67 countries responded. Except for dense fine speckled (DFS), the nuclear competent patterns were reported by > 85% of the laboratories. Except for rods and rings, the cytoplasmic competent patterns were reported by > 72% of laboratories.
Cytoplasmic IIF staining was considered ANA positive by 55% of clinicians and 62% of laboratory professionals, with geographical and expertise-related differences.
Quantification of fluorescence intensity was considered clinically relevant for nuclear patterns, but less so for cytoplasmic and mitotic patterns. Combining IIF with specific extractable nuclear antigens (ENA)/dsDNA antibody testing was considered most informative.
Of the nuclear competent patterns, the centromere and homogeneous pattern obtained the highest scores for clinical relevance and the DFS pattern the lowest. Of the cytoplasmic patterns, the reticular/mitochondria-like pattern obtained the highest scores for clinical relevance and the polar/Golgi-like and rods and rings patterns the lowest.
Conclusion
This survey confirms that the major nuclear and cytoplasmic ANA IIF patterns are considered clinically important. There is no unanimity on classifying DFS, rods and rings and polar/Golgi-like as a competent pattern and on reporting cytoplasmic patterns as ANA IIF positive.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 OLV Hospital, Department of Laboratory Medicine, Aalst, Belgium (GRID:grid.416672.0) (ISNI:0000 0004 0644 9757); KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
2 Sciensano (Formerly Scientific Institute of Public Health), Brussels, Belgium (GRID:grid.508031.f)
3 University of Florida, Department of Oral Biology, Gainesville, USA (GRID:grid.15276.37) (ISNI:0000 0004 1936 8091)
4 Universidade Federal de São Paulo, Escola Paulista de Medicina, Rheumatology Division, Sao Paulo, Brazil (GRID:grid.411249.b) (ISNI:0000 0001 0514 7202)
5 Pontifícia Universidade católica de Goiás, Goiânia, Brazil (GRID:grid.412263.0) (ISNI:0000 0001 2355 1516)
6 MUMC, Centraal Diagnostisch Laboratorium, Maastricht, The Netherlands (GRID:grid.412966.e) (ISNI:0000 0004 0480 1382)
7 University of Turku, Department of Medical Microbiology and Immunology, Turku, Finland (GRID:grid.1374.1) (ISNI:0000 0001 2097 1371)
8 Medical University of Innsbruck, Rheumatology Laboratory, Department of Internal Medicine II, Innsbruck, Austria (GRID:grid.5361.1) (ISNI:0000 0000 8853 2677)
9 University Hospital Basel, Medical Immunology, Laboratory Medicine, Basel, Switzerland (GRID:grid.410567.1)
10 University of Thessaly, Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, Larissa, Greece (GRID:grid.410558.d) (ISNI:0000 0001 0035 6670)
11 Hospital Universitario Araba, Servicio de Reumatología, Vitoria, Spain (GRID:grid.468902.1) (ISNI:0000 0004 1773 0974)
12 Umeå University, Department of Clinical Microbiology, Umeå, Sweden (GRID:grid.12650.30) (ISNI:0000 0001 1034 3451)
13 University Hospital Centre Zagreb, Department of Laboratory Diagnostics, Zagreb, Croatia (GRID:grid.412688.1) (ISNI:0000 0004 0397 9648)
14 East Tallin Central Hospital, Central Laboratory, Tallin, Estonia (GRID:grid.412688.1)
15 Ghent University, Department of Internal Medicine, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798); Ghent University, Department of Diagnostic Sciences, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798)
16 Université Catholique de Louvain, Pôle de Pathologies Rhumatismales Et systémiques, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X); Cliniques Universitaires Saint-Luc, Department of Rheumatology, Brussels, Belgium (GRID:grid.48769.34) (ISNI:0000 0004 0461 6320)
17 GZA Hospitals, Department of Laboratory Medicine, Antwerp, Belgium (GRID:grid.428965.4) (ISNI:0000 0004 7536 2436)
18 University Hospital Liège, Department of Clinical Chemistry, Liège, Belgium (GRID:grid.411374.4) (ISNI:0000 0000 8607 6858)
19 AZ Sint-Jan Hospital Bruges-Ostend, Department of Laboratory Medicine, Bruges, Belgium (GRID:grid.420036.3) (ISNI:0000 0004 0626 3792); Vrije Universiteit Brussel, Research Group Reproductive Immunology and Implantation (REIM), Brussels, Belgium (GRID:grid.8767.e) (ISNI:0000 0001 2290 8069)
20 University Hospital Centre Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia (GRID:grid.412688.1) (ISNI:0000 0004 0397 9648)
21 UK NEQAS Immunology, Northern General Hospital, Sheffield, UK (GRID:grid.412937.a) (ISNI:0000 0004 0641 5987)
22 South Karelia Central Hospital, Department of Medicine, Lappeenranta, Finland (GRID:grid.416155.2) (ISNI:0000 0004 0628 2117)
23 Saint Petersburg State University, Laboratory of the Mosaic of Autoimmunity, Saint-Petersburg, Russian Federation (GRID:grid.15447.33) (ISNI:0000 0001 2289 6897); Sheba Medical Center, Affiliated to Tel-Aviv University School of Medicine, Tel-Hashomer, Zabludowicz Center for Autoimmune Diseases, Tel Aviv, Israel (GRID:grid.413795.d) (ISNI:0000 0001 2107 2845)
24 Laboratorial Germano de Sousa, Centro de Medicina, Lisboa, Portugal (GRID:grid.413795.d)
25 Hospital Universitario Marqués de Valdecilla, Servicio de Inmunología, Santander, Spain (GRID:grid.411325.0) (ISNI:0000 0001 0627 4262)
26 UOC Microbiologia e Virologia, Presidio Ospedaliero San Carlo Borromeo, Milan, Italy (GRID:grid.411325.0)
27 KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); University Hospital Leuven, Department of Laboratory Medicine, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338)